STEM-PD Phase 1 trial advances with positive early safety findings

A Phase 1 clinical trial testing the investigational stem cell-based therapy STEM-PD in people with Parkinson’s disease has advanced to a higher dose following positive findings about the safety of the lower dose, according to a press release from Lund University. Four patients will receive the high dose…

Parkinson’s therapy risvodetinib shows good safety profile in trial

Risvodetinib, an experimental therapy that Inhibikase Therapeutics is developing for Parkinson’s disease, was well tolerated both by healthy volunteers and Parkinson’s patients in a Phase 1 clinical trial. That’s according to the full results from the Inhibikase-funded work, detailed in a study titled “A Phase I, Randomized,…

Extended Dosing Improves Safety of IkT-148009, Animal Studies Show

The safety profile of IkT-148009, an investigational oral medication for Parkinson’s disease, improved the longer the drug was dosed, demonstrating target selectivity, according to interim three-month animal data. The ongoing toxicology studies, conducted by the therapy’s developer, Inhibikase Therapeutics, were designed to meet regulatory requirements for regular…